Trial Profile
To evaluate the efficacy and safety of adding anlotinib to neoadjuvant chemotherapy in patients (pts) with primary TNBC
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Lobaplatin (Primary) ; Docetaxel; Paclitaxel; Taxanes
- Indications Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms neoALTALL
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
- 10 Feb 2023 Status changed from recruiting to active, no longer recruiting, according to Results presented at the 45th Annual San Antonio Breast Cancer Symposium.
- 30 Jun 2022 New trial record